elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Biliary tract cancer
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Biliary tract cancer
RIS
0.002
(Research Intensity Score)
Papers
96
Top papers
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · 1074 citations
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
2022 · 1141 citations
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
2024 · 274 citations
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
2024 · 142 citations
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
2021 · 768 citations
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
2025 · 69 citations
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
2022 · 319 citations
Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer ( KHBO1401 ‐ MITSUBA )
2022 · 247 citations
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
2023 · 118 citations
Newest papers
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
2026 · 1 citations
Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor
2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
2026
Real-World Efficacy and Safety of Gemcitabine, Cisplatin, Plus Immune Checkpoint Inhibitors in Biliary Tract Cancer: A Retrospective Analysis
2026
The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study
2026
The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study
2026
Shared evolutionary trajectories underlying carcinogenesis and metastasis in biliary tract cancer
2026
Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial
2026
Gemcitabine, Cisplatin, and Durvalumab for Alpha-Fetoprotein-Producing Cancer of Unknown Primary Suspected from the Biliary Tract: A Case Report
2026
Browse all papers →
Biliary tract cancer's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Biliary tract cancer's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link